Mineralys Therapeutics entered its Q1 results week with short sellers quietly adding pressure and options traders having already rotated to a more bullish stance — a setup that frames the next catalyst squarely around the FDA.
The week's headline event landed after the close on May 6. Q1 EPS came in at -$0.47, in line with consensus. One headline noted the company beat by $0.34 — a discrepancy likely reflecting different analyst benchmarks — but the Street's overall read was that the print delivered no surprises. MLYS had already gained 13.1% on the week heading into the number, recovering from mid-April weakness. The day-of move was modest, down 1.2% to $29.28, consistent with a market that had priced in the update. The company also announced participation in the BofA Healthcare Conference on May 5, keeping institutional dialogue active ahead of the next regulatory milestone.
The positioning picture entering the week was a study in contrasts. Short interest has been grinding higher — up roughly 18% over the past month to 12.1% of the free float, or around 9.55 million shares. That is a meaningful level for a clinical-stage biotech. Yet the borrow market remains comfortably loose. Cost to borrow is negligible at 0.51%, barely moved on the week, and availability is wide relative to the short position. The 52-week utilization peak of 16.5% is well above the current 6.8% reading, meaning the lending pool has plenty of room. Short sellers are adding, but they are not fighting for shares. Options told a different story: the put/call ratio has dropped sharply to 0.67, well below its 20-day average of 0.89. That shift away from protective puts reflects the stock's recovery from the April lows rather than complacency — PCR had been running above 1.25 for most of April before the price turned.
The Street is uniformly bullish, with the analyst consensus fully on the buy side — zero hold or sell ratings. TD Cowen freshly initiated coverage with a Buy on April 27, the most recent action. BofA raised its target to $51 following the March data read. Goldman Sachs, Wells Fargo, HC Wainwright, and Stifel have all lifted targets over the past several months, with price targets clustering in the $51–$56 range. At $29.28, the stock trades at a roughly 45–80% discount to those targets. That gap reflects binary clinical-stage risk rather than a valuation disagreement — this is not a cheapness play in any traditional sense, and the negative P/E and EV/EBITDA multiples simply confirm the company is pre-revenue. The analyst recommendation differential ranks in the 97th percentile of the universe, meaning the one-sided buy consensus is unusual even by biotech standards.
The ownership flow adds texture to the short-seller story. FMR (Fidelity) added nearly 3 million shares as of April 30, lifting its position to 6.1% of shares outstanding. BlackRock and State Street Global Advisors both added meaningfully in the same filing period. RA Capital — already a 9.3% holder — added 369,000 shares through March. On the insider side, the CEO Jon Congleton sold approximately $1.97 million worth of stock in late March and mid-April, and the CMO made smaller sales in April. The trades are relatively modest in scale and carry a significance score of 2 out of 10, consistent with routine plan-based selling rather than a directional view. The counterweight is RA Capital's 5%-owner purchase of 58,300 shares in late March at $24.16 — a $1.4 million bet placed at a discount to where the stock now trades.
Prior earnings reactions carry a cautionary note. The two most recent data-adjacent events — a March 17 readout and a March 12 announcement — each produced sharp negative moves: down 7.1% on the day and 11.1% over five days in one case, down 6.4% on the day and 16.8% over five days in the other. Both events were tied to clinical or regulatory newsflow rather than financial results. The next confirmed event is May 11, suggesting another data or regulatory update is imminent. With lorundrostat's NDA submission timeline and FDA engagement as the core catalyst, the next print is less about quarterly burn rates and more about whether the agency timeline holds and what the NDA review period implies for a commercial launch window.
What to watch: the nature of the May 11 event — whether it is a regulatory update, a clinical data presentation, or a conference readout — will determine how the elevated short position and recently shifted options market respond in tandem.
See the live data behind this article on ORTEX.
Open MLYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
